207 related articles for article (PubMed ID: 16729147)
1. Design of targeting ligands in medicinal inorganic chemistry.
Storr T; Thompson KH; Orvig C
Chem Soc Rev; 2006 Jun; 35(6):534-44. PubMed ID: 16729147
[TBL] [Abstract][Full Text] [Related]
2. Metal complexes of maltol and close analogues in medicinal inorganic chemistry.
Thompson KH; Barta CA; Orvig C
Chem Soc Rev; 2006 Jun; 35(6):545-56. PubMed ID: 16729148
[TBL] [Abstract][Full Text] [Related]
3. Lanthanides in magnetic resonance imaging.
Bottrill M; Kwok L; Long NJ
Chem Soc Rev; 2006 Jun; 35(6):557-71. PubMed ID: 16729149
[TBL] [Abstract][Full Text] [Related]
4. Prospects of metal complexes peripherally substituted with sugars in biomedicinal applications.
Gottschaldt M; Schubert US
Chemistry; 2009; 15(7):1548-57. PubMed ID: 19130511
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic application of lanthanides.
Fricker SP
Chem Soc Rev; 2006 Jun; 35(6):524-33. PubMed ID: 16729146
[TBL] [Abstract][Full Text] [Related]
6. Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes.
Hermann P; Kotek J; Kubícek V; Lukes I
Dalton Trans; 2008 Jun; (23):3027-47. PubMed ID: 18521444
[TBL] [Abstract][Full Text] [Related]
7. Lanthanide complexes based on a 1,7-diaza-12-crown-4 platform containing picolinate pendants: a new structural entry for the design of magnetic resonance imaging contrast agents.
Mato-Iglesias M; Roca-Sabio A; Pálinkás Z; Esteban-Gómez D; Platas-Iglesias C; Tóth E; de Blas A; Rodríguez-Blas T
Inorg Chem; 2008 Sep; 47(17):7840-51. PubMed ID: 18672876
[TBL] [Abstract][Full Text] [Related]
8. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents.
Peacock AF; Sadler PJ
Chem Asian J; 2008 Nov; 3(11):1890-9. PubMed ID: 18712745
[TBL] [Abstract][Full Text] [Related]
9. Tunable imaging of cells labeled with MRI-PARACEST agents.
Aime S; Carrera C; Delli Castelli D; Geninatti Crich S; Terreno E
Angew Chem Int Ed Engl; 2005 Mar; 44(12):1813-5. PubMed ID: 15723362
[No Abstract] [Full Text] [Related]
10. Editorial: lanthanide compounds for therapeutic and diagnostic applications.
Thompson KH; Orvig C
Chem Soc Rev; 2006 Jun; 35(6):499. PubMed ID: 16729143
[TBL] [Abstract][Full Text] [Related]
11. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents.
Caravan P
Chem Soc Rev; 2006 Jun; 35(6):512-23. PubMed ID: 16729145
[TBL] [Abstract][Full Text] [Related]
12. Bidentate lactate binding in aqueous solution in a cationic, heptadentate lanthanide complex: an effective chiral derivatising agent.
Dickins RS; Love CS; Puschmann H
Chem Commun (Camb); 2001 Nov; (22):2308-9. PubMed ID: 12240049
[TBL] [Abstract][Full Text] [Related]
13. Novel pH-reporter MRI contrast agents.
Aime S; Delli Castelli D; Terreno E
Angew Chem Int Ed Engl; 2002 Nov; 41(22):4334-6. PubMed ID: 12434381
[No Abstract] [Full Text] [Related]
14. From spherical to osmotically shrunken paramagnetic liposomes: an improved generation of LIPOCEST MRI agents with highly shifted water protons.
Terreno E; Cabella C; Carrera C; Delli Castelli D; Mazzon R; Rollet S; Stancanello J; Visigalli M; Aime S
Angew Chem Int Ed Engl; 2007; 46(6):966-8. PubMed ID: 17167807
[No Abstract] [Full Text] [Related]
15. On-resonance low B1 pulses for imaging of the effects of PARACEST agents.
Vinogradov E; Zhang S; Lubag A; Balschi JA; Sherry AD; Lenkinski RE
J Magn Reson; 2005 Sep; 176(1):54-63. PubMed ID: 15979362
[TBL] [Abstract][Full Text] [Related]
16. Equilibrium and kinetic properties of the lanthanoids(III) and various divalent metal complexes of the heptadentate ligand AAZTA.
Baranyai Z; Uggeri F; Giovenzana GB; Bényei A; Brücher E; Aime S
Chemistry; 2009; 15(7):1696-705. PubMed ID: 19130509
[TBL] [Abstract][Full Text] [Related]
17. Benefiting from the unique properties of lanthanide ions.
Bünzli JC
Acc Chem Res; 2006 Jan; 39(1):53-61. PubMed ID: 16411740
[TBL] [Abstract][Full Text] [Related]
18. A novel strategy for the design of 8-hydroxyquinolinate-based lanthanide bioprobes that emit in the near infrared range.
Comby S; Imbert D; Vandevyver C; Bünzli JC
Chemistry; 2007; 13(3):936-44. PubMed ID: 17075929
[TBL] [Abstract][Full Text] [Related]
19. Design of anticancer prodrugs for reductive activation.
Chen Y; Hu L
Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784
[TBL] [Abstract][Full Text] [Related]
20. A categorization of metal anticancer compounds based on their mode of action.
Gianferrara T; Bratsos I; Alessio E
Dalton Trans; 2009 Oct; (37):7588-98. PubMed ID: 19759927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
